Claims for Patent: 8,679,473

Summary for Patent: 8,679,473

Title:	Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof
Abstract:	The invention relates to an non-pathogenic and/or attenuated bacterium which is capable of inducing apoptosis in macrophages.
Inventor(s):	Fensterle; Joachim (Hoechberg, DE), Galmbacher; Katharina (Munich, DE), Rapp; Ulf (Wuerzburg, DE), Goebel; Werner (Munich, DE), Hotz; Christian (Munich, DE)
Assignee:	Aeterna Zentaris GmbH (Frankfurt, DE)
Application Number:	13/364,437
Patent Claims:	1. A method of treating a mammal suffering from a physiological and/or pathophysiological condition, the method comprising non-orally administering at least one non-pathogenic and/or attenuated bacterium, wherein said non-pathogenic and/or attenuated bacterium is capable of inducing apoptosis in a tumor-associated macrophage (TAM); wherein (a) apoptosis is induced in tumor-associated macrophages (TAM) and tumor-associated macrophages (TAM) are partially or nearly completely depleted and/or (b) apoptosis is induced in disease-associated macrophages and disease associated macrophages are partially or nearly completely depleted, wherein the at least one bacterium constitutively expresses IpaB, SipB, or a combination thereof. 2. The method according to claim 1, wherein the at least one bacterium is selected from the group consisting of gram-negative bacterium and gram-positive bacterium. 3. The method according to claim 1, wherein the at least one bacterium is selected from the group consisting of Shigella spp., Salmonella spp., Listeria spp., Mycobacterium spp., Escherichia spp., Yersinia spp., Vibrio spp., and Pseudomonas spp.. 4. The method according to claim 1, wherein the at least one bacterium is selected from the group consisting of Shigella flexneri, Salmonella typhimurium, Mycobacterium bovis BCG, Listeria monocytogenes, Escherichia coli, Salmonella typhi, Yersinia enterocolitica, and Vibrio cholerae. 5. The method according to claim 1, wherein the at least one bacterium is attenuated in its virulence either by a loss of function in at least one virulence factor necessary for infection of the host, by an auxotrophic mutation leading to an impaired growth in a host, or a combination thereof. 6. The method according to claim 1, wherein the attenuation of at least one bacterium is caused by deletion or inactivation of at least one gene selected from the group consisting of aroA, aro, asd, gal, pur, cya, crp, phoP/Q, and omp. 7. The method according to claim 1, wherein the macrophages are M1 macrophages, M2 macrophages, or a combination thereof. 8. The method according to claim 1, wherein the macrophages are M2 macrophages. 9. The method according to claim 1, wherein the induction of apoptosis is achieved by caspase activation. 10. The method according to claim 1, wherein the at least one bacterium is a recombinant bacterium. 11. The method according to claim 1, wherein the at least one bacterium comprises at least one chromosomally integrated DNA encoding at least one protein selected from the group of IpaB and SipB. 12. The method according to claim 11, wherein the chromosomally integrated DNA is a recombinant DNA. 13. The method according to claim 1, wherein the at least one bacterium comprises at least one chromosomal deletion or inactivation of at least one regulatory DNA leading to the constitutive expression of at least one protein selected from the group of IpaB and SipB. 14. The method according to claim 1, wherein the at least one bacterium comprises at least one plasmid wherein the at least one plasmid encodes IpaB, SipB, or a combination thereof. 15. The method according to claim 14, wherein the at least one plasmid encodes at least one regulatory DNA leading to the constitutive expression of IpaB, SipB, or a combination thereof. 16. The method according to claim 1, wherein the at least one bacterium is selected from the group consisting of: Shigella flexneri M90T delta-aroA, Salmonella typhimurium delta-aroA, and Shigella flexneri BS 176 delta-aroA pWR100. 17. The method according to claim 1, wherein the at least one bacterium is provided in lyophilized form. 18. The method according to claim 1, wherein the at least one bacterium is provided in a pharmacologically acceptable buffer for intravenous injection. 19. The method according to claim 1, wherein the physiological and/or pathophysiological condition to be treated is selected from the group consisting of a disease involving macrophage inflammation where macrophages are associated with disease onset or disease progression, a tumor disease, uncontrolled cell division, a malignant tumor, a benign tumor, a solid tumor, a sarcoma, a carcinoma, a hyperproliferative disorder, a carcinoid, Ewing sarcoma, Kaposi sarcoma, a brain tumor, a tumor originating from the brain, a tumor originating from nervous system, a tumors originating from the meninge, a glioma, a neuroblastoma, stomach cancer, kidney cancer, kidney cell carcinomas, prostate cancer, a prostate carcinoma, a connective tissue tumor, a soft tissue sarcoma, a pancreatic tumor, a liver tumor, a head tumor, a neck tumor, oesophageal cancer, thyroid cancer, osteosarcoma, retinoblastoma, thymoma, testicular cancer, lung cancer, bronchial carcinomas, breast cancer, mamma carcinomas, intestinal cancer, a colorectal tumor, colon carcinoma, rectum carcinoma, gynecological tumor, ovarian tumor, uterine cancer, cervical cancer, cervix carcinoma, cancer of the body of the uterus, a corpus carcinoma, an endometrial carcinoma, urinary bladder cancer, bladder cancer, skin cancer, basalioma, spinalioma, melanoma, intraocular melanoma, leukemia, chronic leukemia, acute leukemia, lymphoma, infection, viral infection, bacterial infection, influenza, chronic inflammation, organ rejection, an autoimmune disease, diabetes and diabetes type II. 20. The method according to claim 1, wherein the bacterium is administered before and/or during and/or after administering at least one further pharmacologically active substance. 21. The method according to claim 20, wherein the further pharmacologically active substance is selected from the group consisting of: a DNA topoisomerase I inhibitor, a DNA topoisomerase II inhibitor, a DNA intercalator, an alkylating agent, a microtubuli destabilizer, a hormone receptor agonist, a growth factor receptor agonist, a hormone receptor antagonist, a growth factor receptor agonist, an inhibitor of signal transduction, an antibody against a growth factor, an antibody against a growth factor receptor, a kinase inhibitor, and an antimetabolite. 22. The method according to claim 20, wherein the further pharmacologically active substance is selected from the group consisting of actinomycin D, aminoglutethimide, asparaginase, Bevacizumab, azathioprine, BCNU (carmustine), bleomycin, busulfan, carboplatin, CCNU (lomustine), chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dactinomycin, daunorubicin, diethylstilbestrol, doxorubicin (adriamycin), DTIC (dacarbacin), epirubicin, Cetuximab, erythrohydroxynonyladenine, ethynyloestradiol, etoposide, fludarabine phosphate, fluoxymesterone, flutamide, gemcitabine, Imatinib, trastuzumab, hexamethylmelamine, hydroxyurea, hydroxyprogesterone caproate, idarubicin, ifosfamide, interferon, Gefitinib, irinotecan, L-asparaginase, leucovorin, mechlorethamine, medroxyprogesterone acetate, megestrol acetate, melphalan, mesna, methotrexate, mitomycin C, mitotane, mitoxantrone, N-phosphonoacetyl-L-aspartate (PALA), oxaliplatin, pentostatin, plicamycin, prednisolone, prednisone, procarbazine, raloxifen, rapamycin, semustine, sorafenib, streptozocin, tamoxifen, Erlotinib, Docetaxel, teniposide, testosterone propionate, thioguanine, thiotepa, topotecan, trimethylmelamine, uridine, vinblastine, vincristine, vindesine, vinorelbine, 2',2'-difluorodeoxycytidine,5-fluorodeoxyuridine monophosphate,5-azacytidine cladribine,5-fluorodeoxyuridine, 5-fluorouarcil (5-FU), and 6-mercaptopurine. 23. The method according to claim 1, wherein the at least one bacterium is administered before, during, after or a combination thereof after treating with radiotherapy, surgery, or a combination thereof.

Details for Patent 8,679,473

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2028-01-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2028-01-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2028-01-29
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2028-01-29